Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Company Overview - Bristol Myers Squibb (BMY) is expected to report a year-over-year decline in earnings with a projected EPS of $1.46, reflecting a decrease of 14.1$11.57 billion, which represents a slight increase of 0.8% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 7.02% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bristol Myers is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.43%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Bristol Myers exceeded the expected EPS of $1.49 by delivering$1.80, achieving a surprise of +20.81% [12] - The company has successfully beaten consensus EPS estimates in the last four quarters [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Qiagen (QGEN) is also expected to report earnings of $0.62 per share, reflecting a year-over-year increase of 12.7$520.73 million, up 2.3% from the previous year, with an Earnings ESP of 2.76% indicating a likely earnings beat [18]